ONK Therapeutics believes that the combination of a potent NK cell, with strategies to further enhance its targeting, and the addition of a further patented killing mechanism in TRAIL, to enhance its efficacy in killing tumour cells, would be a very attractive product for major pharmaceutical companies.
The ONK Therapeutics Solution
Making Cell Therapy More Accessible
ONK Therapeutics ONK cell approach provides a low cost, safe, effective, off‐the‐shelf, dose titratable solution that makes cell therapy more accessible.
- Broad patient applicability, low/no CRS risk, no uncontrolled expansion
- Use like a drug (short half life)
- High cancer killing ability
- Batch manufacture in hours, easy distribution, low cost
Why ONK Therapeutics is Different
At the present time, the leading cellular immunotherapy candidates to progress to drug approval are based on human T-cells, which are modified with the addition of Chimeric Antigen Receptors (CARs) forming CAR T cells which can then recognise and destroy cancer cells.
However, despite the fantastic responses seen with CAR-T cells, they have a number of disadvantages relating to safety, manufacturing, cost and delivery, and may not be appropriate for all patients
Given the potential side effects of T-cell therapy, utilizing an alternative type of immune cell, i.e. NK cells, could provide a more ideal solution. NK cells have the potential to be, more effective, safer and more amenable to development as an off-the-shelf therapy, are easier to manufacture and have lower production costs.